Targeted Therapy in Early-Stage Resectable NSCLC: Updates from WCLC 2026 - European Medical Journal

This site is intended for healthcare professionals

Targeted Therapy in Early-Stage Resectable NSCLC: Updates from WCLC 2026

Oncology

This episode has been funded by AstraZeneca and is intended for healthcare professionals. 

All content has been developed independently by AMJ, and AstraZeneca has had no influence over the content of this podcast. The views expressed are those of the participating experts and do not necessarily reflect the views of AMJ or AstraZeneca. This material is intended for educational and scientific exchange purposes only.

For patients with resected EGFR-mutated non–small cell lung cancer, open questions remain on how long to treat, how to keep patients on adjuvant therapy, and what molecular residual disease testing can add. Thoracic oncologists Christine Lovly and Eric Singhi discuss what updates from the World Conference on Lung Cancer (WCLC) 2026 mean for these decisions, with Singhi drawing on real-world data he presented at the meeting. The speakers also cover the role of adjuvant chemotherapy, the timing of biomarker testing in early-stage disease, and neoadjuvant targeted therapy for other oncogenic drivers. Listen to the full episode. 

Speakers:

Christine Lovly1,2


Eric Singhi3,4


  1. Professor, Thoracic Medical Oncology, City of Hope, Duarte, California, USA
  2. Division Chief, Thoracic Medical Oncology, City of Hope, Duarte, California, USA
  3. Assistant Professor, The University of Texas MD Anderson Cancer Center, Houston, USA
  4. Thoracic Medical Oncologist, The University of Texas MD Anderson Cancer Center, Houston, USA

Rate this content's potential impact on patient outcomes

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this content.